Researchers at the University of California, San Diego Moores Cancer Center have identified a humanized monoclonal antibody that targets and directly kills chronic lymphocytic leukemia (CLL) cells. The findings, published in Proceedings of the National Academy of Sciences represent a potential new therapy for treating at least some patients with CLL, the most common type of blood cancer in the United States. Read more here.
Study mentioned: Zhang S, et al. Targeting chronic lymphocytic leukemia cells with a humanized monoclonal antibody specific for CD44. Proc Natl Acad Sci U S A. 2013 Mar 25. [Epub ahead of print] PMID: 23530247
No comments:
Post a Comment